Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months.
Specialty Pharmacy News
AxelaCare enhances OptumRx’s ability to deliver care to the growing number of consumers managing complex conditions through at-home infusions.
Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC.
The moves are part of a strategic move to align efforts for internal improvement, the specialty pharmacy operator said.
A new drug has been approved that, in conjunction with vemurafenib, is meant to treat metastatic melanoma that can't be removed through surgery with a certain gene mutation.
Consider this: 1-in-5 hospital patients end up back in the hospital within 30 days of their discharge. And the biggest factors pulling them back all have to do with medications — either through medication errors, nonadherence or adverse drug events.
The combination of Cotellic with Zelboraf helps patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of one year (12.3 months) without their disease worsening, compared to 7.2 months with Zelboraf alone.
Novira is a company working on curative treatments for chronic hepatitis B.
Genoa said that the acquisition was part of its strategy to improve patient care at the community mental health centers it partners with amid a shortage of psychiatry providers. The acquisition marks the launch of Genoa Telepsychiatry.